CervoMed Q4/FY2025 net loss widens to $27M; cash runway ~6 months; Phase 3 DLB trial pending financing

CervoMed Inc.

FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.
FDA alignment obtained for planned Phase 3 DLB trial; initiation in H2 2026 subject to funding.
Selected 50mg TID neflamapimod dose for Phase 3; additional data to be presented at AD/PD 2026.
Topline data expected H2 2026 from Phase 2a RAS and nfvPPA trials; ALS trial start by YE 2026.
Grant revenue fell to $4.0M from $9.7M due to RewinD-LB completion; R&D spend rose to $21.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.